Prolonged use did not substantially change this risk. After discontinuation of dopaminergic treatment, the increased risk of hip/femur fractures rapidly decreased and it was no longer increased after 1 year of discontinuation. this website patients who used dopaminergic drugs and antidepressants at the same time had a 3.5-fold increased P5091 research buy risk of hip/femur fracture. The findings of this study are to some extent in line with the findings

of Vestergaard and coworkers [17]. They reported an association between levodopa use and an increased overall fracture risk and an increased hip fracture risk with high doses of levodopa. In addition, they found an association between dopamine agonists in median dose and an increased hip fracture risk. In our study, the duration of use in current dopaminergic drug users did not substantially change the risk of hip/femur fractures. We did notice an increase of the risk estimate directly after initiation of the dopaminergic drug, suggesting that falls are responsible for the increase in fracture risk and not changes in BMD. This may be explained by the fact that dopaminergic drugs could cause postural hypotension, sudden onset

of sleep, daytime sleepiness and dizziness, which may lead to an increased risk of falling [34]. One may expect that postural hypotension occurs almost directly after initiation of dopaminergic drug treatment. The timing SB-715992 order of use was found to be important: only current use was associated with a nearly twofold increased risk hip/femur fractures, and the increased risk of hip/femur fractures rapidly decreased after discontinuation. This corroborates the hypothesis that the increased risk is caused by an increased risk of falling rather than an effect on BMD. Unfortunately, we could not formally test this hypothesis due the absence of data on both

falls and BMD in our data source. As a result of potential improvement of BMD due to suppression Tobramycin of prolactin, we hypothesised that dopaminergic drugs could decrease the risk of hip/femur fractures [17, 18]. Even if dopaminergics have a benefit on BMD, it was not sufficient to reduce fracture risk or to balance the increase in fracture risk assumed to be a consequence of an increased falls risk during the first 6–12 months of use. In contrast, it was suggested that levodopa-induced hyperhomocysteinemia could increase the risk of fracture through a direct effect on the bone collagen cross-links [16]. However, in our study, the risk estimate for levodopa users was not different from that of dopamine agonist users alone, or the users of the combination of dopamine agonists and levodopa. Thus, our data do not support this hypothesis. A remark should be made that the group of users of monotherapy dopamine agonists was relatively small. A substantial number of patients with PD suffer from depression and use antidepressants.